443 related articles for article (PubMed ID: 17420779)
1. Differential effects of selective oestrogen receptor modulators (SERMs) tamoxifen, ospemifene and raloxifene on human osteoclasts in vitro.
Michael H; Härkönen PL; Kangas L; Väänänen HK; Hentunen TA
Br J Pharmacol; 2007 Jun; 151(3):384-95. PubMed ID: 17420779
[TBL] [Abstract][Full Text] [Related]
2. Estrogen and testosterone use different cellular pathways to inhibit osteoclastogenesis and bone resorption.
Michael H; Härkönen PL; Väänänen HK; Hentunen TA
J Bone Miner Res; 2005 Dec; 20(12):2224-32. PubMed ID: 16294275
[TBL] [Abstract][Full Text] [Related]
3. Effect of ormeloxifene on ovariectomy-induced bone resorption, osteoclast differentiation and apoptosis and TGF beta-3 expression.
Narayana Murthy PS; Sengupta S; Sharma S; Singh MM
J Steroid Biochem Mol Biol; 2006 Aug; 100(4-5):117-28. PubMed ID: 16797179
[TBL] [Abstract][Full Text] [Related]
4. Importance of membrane- or matrix-associated forms of M-CSF and RANKL/ODF in osteoclastogenesis supported by SaOS-4/3 cells expressing recombinant PTH/PTHrP receptors.
Itoh K; Udagawa N; Matsuzaki K; Takami M; Amano H; Shinki T; Ueno Y; Takahashi N; Suda T
J Bone Miner Res; 2000 Sep; 15(9):1766-75. PubMed ID: 10976996
[TBL] [Abstract][Full Text] [Related]
5. Characterization of circulating human osteoclast progenitors: development of in vitro resorption assay.
Husheem M; Nyman JK; Vääräniemi J; Vaananen HK; Hentunen TA
Calcif Tissue Int; 2005 Mar; 76(3):222-30. PubMed ID: 15692727
[TBL] [Abstract][Full Text] [Related]
6. BSP and RANKL induce osteoclastogenesis and bone resorption synergistically.
Valverde P; Tu Q; Chen J
J Bone Miner Res; 2005 Sep; 20(9):1669-79. PubMed ID: 16059638
[TBL] [Abstract][Full Text] [Related]
7. Tumor necrosis factor-alpha: alternative role as an inhibitor of osteoclast formation in vitro.
Balga R; Wetterwald A; Portenier J; Dolder S; Mueller C; Hofstetter W
Bone; 2006 Aug; 39(2):325-35. PubMed ID: 16580896
[TBL] [Abstract][Full Text] [Related]
8. Human microvascular endothelial cell activation by IL-1 and TNF-alpha stimulates the adhesion and transendothelial migration of circulating human CD14+ monocytes that develop with RANKL into functional osteoclasts.
Kindle L; Rothe L; Kriss M; Osdoby P; Collin-Osdoby P
J Bone Miner Res; 2006 Feb; 21(2):193-206. PubMed ID: 16418775
[TBL] [Abstract][Full Text] [Related]
9. Estradiol and raloxifene decrease the formation of multinucleate cells in human bone marrow cultures.
Ramalho AC; Couttet P; Baudoin C; Morieux C; Graulet AM; de Vernejoul MC; Cohen-Solal ME
Eur Cytokine Netw; 2002; 13(1):39-45. PubMed ID: 11956019
[TBL] [Abstract][Full Text] [Related]
10. Analysis of estrogen agonism and antagonism of tamoxifen, raloxifene, and ICI182780 in endometrial cancer cells: a putative role for the epidermal growth factor receptor ligand amphiregulin.
Gielen SC; Burger CW; Kühne LC; Hanifi-Moghaddam P; Blok LJ
J Soc Gynecol Investig; 2005 Oct; 12(7):e55-67. PubMed ID: 16202921
[TBL] [Abstract][Full Text] [Related]
11. Selective estrogen receptor modulators prevent neointima formation after vascular injury.
Savolainen-Peltonen H; Luoto NM; Kangas L; Häyry P
Mol Cell Endocrinol; 2004 Nov; 227(1-2):9-20. PubMed ID: 15501580
[TBL] [Abstract][Full Text] [Related]
12. Osteoclast differentiation factor (ODF) induces osteoclast-like cell formation in human peripheral blood mononuclear cell cultures.
Matsuzaki K; Udagawa N; Takahashi N; Yamaguchi K; Yasuda H; Shima N; Morinaga T; Toyama Y; Yabe Y; Higashio K; Suda T
Biochem Biophys Res Commun; 1998 May; 246(1):199-204. PubMed ID: 9600092
[TBL] [Abstract][Full Text] [Related]
13. Osteoclast formation and bone resorption are inhibited by megakaryocytes.
Beeton CA; Bord S; Ireland D; Compston JE
Bone; 2006 Nov; 39(5):985-990. PubMed ID: 16870519
[TBL] [Abstract][Full Text] [Related]
14. Mechanism of osteoclast mediated bone resorption--rationale for the design of new therapeutics.
Väänänen K
Adv Drug Deliv Rev; 2005 May; 57(7):959-71. PubMed ID: 15876398
[TBL] [Abstract][Full Text] [Related]
15. IL-3 inhibits human osteoclastogenesis and bone resorption through downregulation of c-Fms and diverts the cells to dendritic cell lineage.
Gupta N; Barhanpurkar AP; Tomar GB; Srivastava RK; Kour S; Pote ST; Mishra GC; Wani MR
J Immunol; 2010 Aug; 185(4):2261-72. PubMed ID: 20644169
[TBL] [Abstract][Full Text] [Related]
16. Comparative study of the short-term effects of a novel selective estrogen receptor modulator, ospemifene, and raloxifene and tamoxifen on rat uterus.
Zheng H; Kangas L; Härkönen PL
J Steroid Biochem Mol Biol; 2004 Feb; 88(2):143-56. PubMed ID: 15084346
[TBL] [Abstract][Full Text] [Related]
17. Fibroblastic stromal cells express receptor activator of NF-kappa B ligand and support osteoclast differentiation.
Quinn JM; Horwood NJ; Elliott J; Gillespie MT; Martin TJ
J Bone Miner Res; 2000 Aug; 15(8):1459-66. PubMed ID: 10934644
[TBL] [Abstract][Full Text] [Related]
18. 17beta-estradiol downregulates beta3-integrin expression in differentiating and mature human osteoclasts.
Saintier D; Burde MA; Rey JM; Maudelonde T; de Vernejoul MC; Cohen-Solal ME
J Cell Physiol; 2004 Feb; 198(2):269-76. PubMed ID: 14603529
[TBL] [Abstract][Full Text] [Related]
19. Effect of high phosphate concentration on osteoclast differentiation as well as bone-resorbing activity.
Kanatani M; Sugimoto T; Kano J; Kanzawa M; Chihara K
J Cell Physiol; 2003 Jul; 196(1):180-9. PubMed ID: 12767054
[TBL] [Abstract][Full Text] [Related]
20. Raloxifene concurrently stimulates osteoprotegerin and inhibits interleukin-6 production by human trabecular osteoblasts.
Viereck V; Gründker C; Blaschke S; Niederkleine B; Siggelkow H; Frosch KH; Raddatz D; Emons G; Hofbauer LC
J Clin Endocrinol Metab; 2003 Sep; 88(9):4206-13. PubMed ID: 12970288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
